文献速递胸部肿瘤

双相型间皮瘤诊断可重复性新见解:国际间皮瘤专家组多机构评估

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
PubMed 文献 · J Thorac Oncol · 2018-04-30

国际间皮瘤专家组对42例原诊断为双相型间皮瘤(BMM)的手术活检样本进行数字切片审阅,14位专家共给出544次诊断,观察者间一致性为中等(加权Kappa=0.45)。BMM中肉瘤样成分小于80%与较好生存相关(p=0.02),过渡性亚型(TMM)提示预后不良,多因素分析风险比=3.2(95%CI 1.6-8.0,p=0.003)。

要点

  • 14位专家对BMM诊断的观察者间一致性为中等(加权Kappa=0.45)。
  • BMM中肉瘤样成分小于80%与较好生存相关(p=0.02)。
  • TMM形态是预后不良指标,多因素分析风险比=3.2(95%CI 1.6-8.0,p=0.003)。

核心结论

  • 国际与法国间皮瘤专家组的一致性支持更新BMM定义以更好进行风险分层和治疗决策。
  • FISH检测CDKN2A(p16)纯合缺失有助于在疑难病例中区分良性反应性间质与真性肉瘤样成分。
  • 过渡性模式(TMM)作为预后不良指标的概念得到进一步验证。

研究设计与样本

  • 研究由国际间皮瘤专家组开展,获法国国家癌症研究所、罕见癌症网络(EURACAN)支持,并与国际肺癌研究协会(IASLC)合作。
  • 从1998至2016年收集的971例BMM中随机选取42例经MESOPATH专家评估肉瘤样成分的手术活检样本。
  • 14位国际间皮瘤病理专家在不知既往诊断和结局的情况下审阅数字扫描切片(HE和pan-cytokeratin染色)。
  • 至少7/14位专家识别出TMM特征的病例被归为TMM组。
  • 采用Kappa统计评估观察者间一致性,Cox回归(校正年龄和性别)进行生存分析。

主要发现

  • 14位专家共记录544次诊断,观察者间相关性为中等(加权Kappa=0.45)。
  • 原MESOPATH诊断为BMM的病例中,审阅者一致同意71%(385/544),分类为纯上皮样17%(93/544),纯肉瘤样12%(66/544)。
  • 23%的病例仅凭形态学或IHC诊断BMM,77%(402/544)需额外IHC评估。
  • 42例BMM的中位总生存(OS)为8个月,与肉瘤样间皮瘤和上皮样间皮瘤的OS显著不同(p<0.0001)。
  • BMM中肉瘤样成分小于80%与较好生存相关(p=0.02)。

关键数值与推荐

  • BMM中肉瘤样成分小于80%与较好生存相关(p=0.02)。
  • TMM形态预后不良风险比=3.2(95%CI 1.6-8.0,p=0.003)。
  • 肉瘤样成分中CDKN2A(p16)纯合缺失风险比=4.5(95%CI 1.2-16.3,p=0.02)。
  • BMM伴TMM中位生存6个月,不伴TMM中位生存12个月(p<0.0001)。
  • CDKN2A(p16)纯合缺失在总病例中检出74%。

临床怎么用

  • BMM诊断需结合形态学与IHC,并建议多专家审阅以提高一致性。
  • 对BMM应评估肉瘤样成分比例,小于80%提示较好生存。
  • 识别TMM形态有助于识别预后不良患者,指导治疗决策。
  • 在疑难病例中可用FISH检测CDKN2A(p16)纯合缺失辅助区分真性肉瘤样成分。

局限性

  • 样本量较小(42例BMM)。
  • 观察者间一致性仅为中等(加权Kappa=0.45)。
  • 研究为回顾性设计,来自单一时段和数据库。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The 2015 WHO classification of tumors categorized malignant mesothelioma into epithelioid, biphasic (BMM), and sarcomatoid (SMM) for prognostic relevance and treatment decisions. The survival of BMM is suspected to correlate with the amount of the sarcomatoid component. The criteria for a sarcomatoid component and the interobserver variability between pathologists for identifying this component are not well described. In ambiguous cases, a "transitional" (TMM) subtype has been proposed but was not accepted as a specific subtype in the 2015 WHO classification. The aims of this study were to evaluate the interobserver agreement in the diagnosis of BMM, to determine the nature and the significance of TMM subtype, and to relate the percentage of sarcomatoid component with survival. The value of staining for BRCA-1-associated protein (BAP1) and CDKN2A(p16) fluorescence in situ hybridization (FISH) were also assessed with respect to each of the tumoral components. METHODS: The study was conducted by the International Mesothelioma Panel supported by the French National Cancer Institute, the network of rare cancer (EURACAN) and in collaboration with the International Association for the Study of Lung Cancer (IASLC). The patient cases include a random group of 42 surgical biopsy samples diagnosed as BMM with evaluation of SMM component by the French Panel of MESOPATH experts was selected from the total series of 971 BMM cases collected from 1998 to 2016. Fourteen international pathologists with expertise in mesothelioma reviewed digitally scanned slides (hematoxylin and eosin - stained and pan-cytokeratin) without knowledge of prior diagnosis or outcome. Cases with at least 7 of 14 pathologists recognizing TMM features were selected as a TMM group. Demographic, clinical, histopathologic, treatment, and follow-up data were retrieved from the MESOBANK database. BAP1 (clone C-4) loss and CDKN2A(p16) homozygous deletion (HD) were assessed by immunohistochemistry (IHC) and FISH, respectively. Kappa statistics were applied for interobserver agreement and multivariate analysis with Cox regression adjusted for age and gender was performed for survival analysis. RESULTS: The 14 panelists recorded a total of 544 diagnoses. The interobserver correlation was moderate (weighted Kappa = 0.45). Of the cases originally classified as BMM by MESOPATH, the reviewers agreed in 71% of cases (385 of 544 opinions), with cases classified as pure epithelioid in 17% (93 of 544), and pure sarcomatoid in 12% (66 of 544 opinions). Diagnosis of BMM was made on morphology or IHC alone in 23% of the cases and with additional assessment of IHC in 77% (402 of 544). The median overall survival (OS) of the 42 BMM cases was 8 months. The OS for BMM was significantly different from SMM and epithelioid malignant mesothelioma (p < 0.0001). In BMM, a sarcomatoid component of less than 80% correlated with a better survival (p = 0.02). There was a significant difference in survival between BMM with TMM showing a median survival at 6 months compared to 12 months for those without TMM (p < 0.0001). BAP1 loss was observed in 50% (21 of 42) of the total cases and in both components in 26%. We also compared the TMM group to that of more aggressive patterns of epithelioid subtypes of mesothelioma (solid and pleomorphic of our large MESOPATH cohort). The curve of transitional type was persistently close to the OS curve of the sarcomatoid component. The group of sarcomatoid, transitional, and pleomorphic mesothelioma were very close to each other. We then considered the contribution of BAP1 immunostaining and loss of CDKN2A(p16) by FISH. BAP1 loss was observed in 50% (21 of 41) of the total cases and in both component in 27% of the cases (11 of 41). There was no significant difference in BAP1 loss between the TMM and non-TMM groups. HD CDKN2A(p16) was detected in 74% of the total cases with no significant difference between the TMM and non-TMM groups. In multivariate analysis, TMM morphology was an indicator of poor prognosis with a hazard ratio = 3.2; 95% confidence interval: 1.6 - 8.0; and p = 0.003 even when compared to the presence of HD CDKN2A(p16) on sarcomatoid component (hazard ratio = 4.5; 95% confidence interval: 1.2 - 16.3, p = 0.02). CONCLUSIONS: The interobserver concordance among the international mesothelioma and French mesothelioma panel suggests clinical utility for an updated definition of biphasic mesothelioma that allows better stratification of patients into risk groups for treatment decisions, systemic anticancer therapy, or selection for surgery or palliation. We also have shown the usefulness of FISH detection of CDKN2A(p16) HD compared to BAP1 loss on the spindle cell component for the separation in ambiguous cases between benign florid stromal reaction from true sarcomatoid component of biphasic mesothelioma. Taken together our results further validate the concept of transitional pattern as a poor prognostic indicator.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Galateau Salle F, Le Stang N, Nicholson AG, et al. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center. J Thorac Oncol. 2018. PMID: 29723687. doi:10.1016/j.jtho.2018.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。